Latest Denosumab Stories

2010-05-20 17:08:00

THOUSAND OAKS, Calif., May 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company's oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4( )- 8, 2010 in Chicago. "Cancer is a complex disease that requires a comprehensive approach.

2010-05-14 15:03:00

THOUSAND OAKS, Calif., May 14 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor.

2010-04-19 15:04:00

THOUSAND OAKS, Calif., April 19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL.

2010-02-19 17:06:00

THOUSAND OAKS, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S.

2010-02-16 04:11:00

DALLAS, February 16, 2010 /PRNewswire/ -- - ReportsandReports announce to have Pipeline/Commercial Insight: Supportive Care in Oncology - Innovation and market growth limited to bone metastases management and emerging supportive care challenges ( http://www.reportsandreports.com/market-reports/pipeline-commercial-insight-s upportive-care-in-oncology-innova/) Market Research Report in its store (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into...

2009-12-18 06:06:00

THOUSAND OAKS, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Amgen Inc.

2009-12-10 12:30:00

SAN ANTONIO, Dec. 10 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer.

2009-12-10 12:30:00

An estimated 70 to 80 percent of patients with advanced or stage four breast cancer develop bone metastases. Bone metastases occurs when the disease progresses to a patient's bones.

2009-11-23 14:05:00

THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a Nov. 18 ceremony in London.

Word of the Day
  • Sleep; the state or condition of being asleep.
  • The state or condition of numbness of a part due to pressure on a nerve: as, the obdormition of a limb.
The word 'obdormition' comes from a Latin word meaning "to fall asleep".